NCT06299631Completed
Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease
Endoscopic Relapse Risk Factors After Ileocolic Resection on Crohn's Disease Patients in the Biologic Era
Source: ClinicalTrials.gov · Last updated 8 Mar 2024
Brief summary (registry, in English)
Aim of the study: To evaluate risk factors of endoscopic relapse after ileocolic resection in a cohort of Crohn's disease patients treated with anti-TNF agents. Methods: From 2014 to 2022, all consecutive patients who underwent ileocolic resection for Crohn's disease treated with anti-TNF agents in two referral tertiary center were prospectively collected. Considering exclusion criteria, data from 114 patients were analyzed. The cohort was separated into 2 groups according to study period. Short and long-term outcomes were compared between the two groups. Primary outcome: Endoscopic recurrence (defined as \> i2 lesions according to Rutgeerts classification) 6 months after surgery
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 133 (actual)
- First submitted
- 29 Nov 2023
- Start date
- Jan 2015
- Primary completion date
- Jun 2023
- Lead sponsor
- University Hospital, Montpellier
- Diseases
- Crohn's disease
- NCT number
- NCT06299631
What you commit to
- Study type: Observational
- Participants enrolled: 133
- From Jan 2015 to the primary completion date, Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Minor patients under 18 years of age
Other
- Endoscopic follow-up not possible
- Pregnant women
- Medical treatment other than anti-TNF alpha
Who the study is looking for
- Patients with histologically proven Crohn's disease
- On anti-TNF alpha: infliximab, adalimumab (ECCO 2014 recommendation)
- \> 18 years old patients
- All patients who have undergone ileocolic resection and whose disease site is accessible to endoscopic follow-up (first or repeat procedure)
Age in the registry: 18 years to 99 years · Sex: All
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Montpellier University Hospital Coordinator of this site? Confirm its status | Montpellier | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.